Text Version
Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby
Related Resources Order Documents NLM
Gateway TOXNET Consumer
Health Clinical Alerts ClinicalTrials.gov PubMed
Central
Privacy Policy
|
|
-
-
Sertraline-induced
hypoglycemia.
Pollak PT, Mukherjee SD, Fraser
AD.
Department of Medicine, College of Pharmacy, Dalhousie
University, Queen Elizabeth II Health Sciences Centre, Halifax, Nova
Scotia, Canada. amiokinectics@hotmail.com
OBJECTIVE: To report a
case of hypoglycemia that occurred in a patient treated with the
selective serotonin-reuptake inhibitor, sertraline. CASE SUMMARY: An
82-year-old white woman with mild cardiovascular disease and no history
of glucose intolerance was seen in the emergency department for a
presyncopal episode associated with a blood glucose of 32 mg/dL as
measured by the ambulance attendant. She had similar symptoms the day
before. Despite repeated administration of oral and intravenous glucose,
the patient had recurrent episodes of hypoglycemia and was hospitalized
for four days. She had started taking sertraline 50 mg once daily for
mild depression 25 days prior to presentation. Other medications
included furosemide 20 mg/d, ramipril 5 mg/d, clopidogrel 75 mg/d,
nitroglycerin patch 0.4 mg/h, and lorazepam 1 mg taken occasionally for
agitation. She had never been prescribed any oral hypoglycemic agents.
Serum sertraline and desmethylsertraline concentrations measured two,
three, and four days after discontinuing sertraline were within the
expected range, but the rate of decline was consistent with a moderately
prolonged half-life. DISCUSSiON: Sertraline has been shown to blunt
postprandial hyperglycemia in rats and to potentiate the hypoglycemic
effects of sulfonylurea agents in humans. It has not been reported to
cause hypoglycemia independently, but in this case, a nondiabetic
patient experienced multiple episodes of hypoglycemia that resolved
after discontinuation of sertraline. CONCLUSIONS: This report and
another implicating fluoxetine in a case of hypoglycemia suggest that
healthcare professionals should consider these medications among the
possible causes of hypoglycemia occurring in patients receiving
selective serotonin-reuptake inhibitors.
Publication Types:
PMID: 11724085 [PubMed - indexed for
MEDLINE]
|